K R Rai

Summary

Affiliation: Long Island Jewish Medical Center
Country: USA

Publications

  1. ncbi request reprint Interferon in the treatment of hairy-cell leukemia
    Shahid Ahmed
    Division of Hematology Oncology, Long Island Jewish Medical Center, 270 05, 76th Ave, New Hyde Park, NY 11040, USA
    Best Pract Res Clin Haematol 16:69-81. 2003
  2. ncbi request reprint Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Michael J Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3554-61. 2002
  3. ncbi request reprint Clinical staging and prognostic markers in chronic lymphocytic leukemia
    Kanti R Rai
    Long Island Jewish Medical Center, Division of Hematology Oncology, 270 05 76th Avenue, New Hyde Park, NY 11040, USA
    Hematol Oncol Clin North Am 18:795-805, vii. 2004
  4. ncbi request reprint Chronic lymphocytic leukemia: current and emerging treatment approaches
    Neil E Kay
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
  5. ncbi request reprint Introduction: Chronic lymphocytic leukemia in perspective
    Kanti R Rai
    Division of Hematology Oncology, Long Island Jewish Med Center, New Hyde Park, NY 11040, USA
    Best Pract Res Clin Haematol 20:363-5. 2007
  6. ncbi request reprint Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy
    Kanti R Rai
    Division of Hematology Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    Exp Hematol 35:134-6. 2007
  7. ncbi request reprint Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    K R Rai
    Cancer and Leukemia Group B, Chicago, USA
    N Engl J Med 343:1750-7. 2000
  8. ncbi request reprint Future prospects for alemtuzumab (MabCampath)
    Kanti Rai
    Long Island Jewish Medical Center New Hyde Park, NY 11042, USA
    Med Oncol 19:S57-63. 2002
  9. ncbi request reprint Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia
    Kanti R Rai
    Division of Hematology Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    Semin Oncol 33:S15-22. 2006
  10. ncbi request reprint Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
    K R Rai
    Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    J Clin Oncol 20:3891-7. 2002

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Interferon in the treatment of hairy-cell leukemia
    Shahid Ahmed
    Division of Hematology Oncology, Long Island Jewish Medical Center, 270 05, 76th Ave, New Hyde Park, NY 11040, USA
    Best Pract Res Clin Haematol 16:69-81. 2003
    ..In this chapter, we discuss the efficacy of interferon and its response duration, toxicity and possible mechanism of action in patients with hairy-cell leukemia...
  2. ncbi request reprint Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Michael J Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3554-61. 2002
    ..Alemtuzumab induced significant responses in these patients with clinical benefit in the majority and with acceptable toxicity in a high-risk group...
  3. ncbi request reprint Clinical staging and prognostic markers in chronic lymphocytic leukemia
    Kanti R Rai
    Long Island Jewish Medical Center, Division of Hematology Oncology, 270 05 76th Avenue, New Hyde Park, NY 11040, USA
    Hematol Oncol Clin North Am 18:795-805, vii. 2004
    ..In this article we provide a brief review of the two staging systems in chronic lymphocytic leukemia, and we discuss the more recently identified, new prognostic markers that are of interest to clinicians and researchers in this field...
  4. ncbi request reprint Chronic lymphocytic leukemia: current and emerging treatment approaches
    Neil E Kay
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Novel agents with unique, nonoverlapping mechanisms of action (eg, oblimersen sodium, lenalidomide, HuMax-CD20, GX15-070), and other treatments are under investigation in an attempt to further improve outcomes...
  5. ncbi request reprint Introduction: Chronic lymphocytic leukemia in perspective
    Kanti R Rai
    Division of Hematology Oncology, Long Island Jewish Med Center, New Hyde Park, NY 11040, USA
    Best Pract Res Clin Haematol 20:363-5. 2007
    ....
  6. ncbi request reprint Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy
    Kanti R Rai
    Division of Hematology Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    Exp Hematol 35:134-6. 2007
  7. ncbi request reprint Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    K R Rai
    Cancer and Leukemia Group B, Chicago, USA
    N Engl J Med 343:1750-7. 2000
    ..We compared the efficacy of fludarabine with that of chlorambucil in the primary treatment of chronic lymphocytic leukemia...
  8. ncbi request reprint Future prospects for alemtuzumab (MabCampath)
    Kanti Rai
    Long Island Jewish Medical Center New Hyde Park, NY 11042, USA
    Med Oncol 19:S57-63. 2002
    ....
  9. ncbi request reprint Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia
    Kanti R Rai
    Division of Hematology Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    Semin Oncol 33:S15-22. 2006
    ..A number of clinical trials are under way assessing the role of alemtuzumab in these settings...
  10. ncbi request reprint Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
    K R Rai
    Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    J Clin Oncol 20:3891-7. 2002
    ....
  11. ncbi request reprint Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up
    M A Hoffman
    Department of Medicine, Long Island Jewish Medical Center Campus of the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
    J Clin Oncol 15:1138-42. 1997
    ..To analyze initial and long-term outcomes after treatment of patients with active hairy-cell leukemia (HCL) with a single cycle of cladribine (2-CdA)...
  12. ncbi request reprint The role of monoclonal antibodies in stem cell transplantation
    Tarun Wasil
    Long Island Jewish Medical Center, Division of Hematology Oncology, New Hyde Park, NY 11040, USA
    Semin Oncol 31:83-9. 2004
    ..This review focuses on the currently available data for in vitro and in vivo purging with these antibodies as well as their role in modulating graft-versus-host disease (GVHD)...
  13. ncbi request reprint Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia
    N Gupta
    Division of Hematology Oncology, Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA
    Leukemia 16:2092-5. 2002
    ..Retreatment with RCD was also effective in achieving a response on relapse of AIHA. Our results indicate that a rituximab-based combination regimen (RCD) is highly effective in treating steroid refractory AIHA of CLL...
  14. ncbi request reprint Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia
    Liguang Chen
    Division of Hematology Oncology, Department of Medicine, University of California, San Diego for the CLL Research Consortium, San Diego, CA, USA
    Blood 100:4609-14. 2002
    ....
  15. ncbi request reprint Campath-1H for chronic lymphocytic leukemia
    Kanti R Rai
    Clin Lymphoma 3:73-4. 2002
  16. ncbi request reprint Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
    Robert E Martell
    Geriatrics Research, Education and Clinical Center, Veterans Affairs Medical Center and Hematology Oncology Division, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 50:37-45. 2002
    ..We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL...
  17. ncbi request reprint Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
    Susan O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:1114-20. 2007
    ..We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL...
  18. ncbi request reprint Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
    Susan M O'Brien
    M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030 7305, USA
    J Clin Oncol 23:7697-702. 2005
    ..To determine the maximum-tolerated dose (MTD), efficacy, safety, and pharmacokinetics of oblimersen sodium in patients with advanced chronic lymphocytic leukemia (CLL)...
  19. pmc CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells
    Rajendra N Damle
    Laboratory of Experimental Immunology, The Feinstein Institute for Medical Research, North Shore Long Island Jewish LIJ Health System, 350 Community Drive, Manhasset, NY 11030, USA
    Blood 110:3352-9. 2007
    ..These findings may help explain why high percentages of CD38(+) cells within clones are associated with poor clinical outcome...
  20. pmc Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection
    Emanuela M Ghia
    Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA
    Blood 111:5101-8. 2008
    ....
  21. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
  22. pmc Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
    Laura Z Rassenti
    The Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA
    Blood 112:1923-30. 2008
    ....
  23. ncbi request reprint The natural history of CLL and new prognostic markers
    Kanti R Rai
    Clin Adv Hematol Oncol 6:4-5; quiz 10-2. 2008
  24. pmc Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status
    Davorka Messmer
    The Laboratory of Experimental Immunology, Institute for Medical Research, North Shore LIJ Health System, Manhasset, New York, USA
    Mol Med 10:96-103. 2004
    ..Our data show that DCs generated from the B-CLL subgroup with unmutated Ig V genes are functionally normal. These results are very promising for the use of DCs from patients with poor prognosis for immunotherapy...
  25. ncbi request reprint Malignant pleural effusions in lymphoproliferative disorders
    Shahid Ahmed
    Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, SK, Canada
    Leuk Lymphoma 46:1039-44. 2005
    ..Many clinical and cytochemical markers have discriminatory values in identifying malignant effusion. A high pleural fluid to serum LDH level correlates with malignant pleural involvement and hospital mortality...
  26. ncbi request reprint Chronic lymphocytic leukemia
    Nicholas Chiorazzi
    Institute for Medical Research, North Shore LIJ Health System, Manhasset, NY 11030, USA
    N Engl J Med 352:804-15. 2005
  27. ncbi request reprint B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes
    Rajendra N Damle
    North Shore Long Island Jewish Research Institute, Manhasset, NY 11030, USA
    Blood 99:4087-93. 2002
    ....
  28. ncbi request reprint Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
    Vicki A Morrison
    Section of Hematology Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Clin Oncol 20:3878-84. 2002
    ..A series of patients enrolled onto an intergroup CLL trial were examined for this complication...
  29. ncbi request reprint Determining the clinical course and outcome in chronic lymphocytic leukemia
    Kanti R Rai
    N Engl J Med 348:1797-9. 2003
  30. ncbi request reprint Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone
    Emilia Albesiano
    North Shore Long Island Jewish Research Institute, 350 Community Dr, Manhasset, NY 11030, USA
    Blood 102:3333-9. 2003
    ..These data suggest that AID-mediated DNA alterations may occur in a variably sized, minor subset of B-CLL cells at any given time...
  31. ncbi request reprint Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations
    Rajendra N Damle
    North Shore Long Island Jewish Research Institute, 350 Community Dr, Manhasset, NY 11030, USA
    Blood 103:375-82. 2004
    ..In addition, they reinforce the concept that B-CLL is not simply an accumulative disease of slowly dividing B lymphocytes but possibly one of B cells with extensive proliferative histories...
  32. ncbi request reprint Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor
    William P Schiemann
    Department of Pediatrics, Program in Cell Biology, National Jewish Medical and Research Center, Goodman Building, K1011, 1400 Jackson Street, Denver, CO 80206, USA
    Cancer Detect Prev 28:57-64. 2004
    ..Our results demonstrate that TGF-beta-resistant B-CLL is linked to signal sequence mutations within the TbetaR-I gene, and may eventually be employed as a prognostic indicator in B-CLL...
  33. pmc Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia
    Fabio Ghiotto
    Department of Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA
    J Clin Invest 113:1008-16. 2004
    ....
  34. ncbi request reprint Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease
    Shahid Ahmed
    Saskatoon Cancer Center, University of Saskatchewan Campus, 20 Campus Drive, Saskatoon, SK, Canada S7N4 H4
    Eur J Cancer 40:1320-6. 2004
    ..It appears that BALT lymphoma tends to be localised to lung at the time of diagnosis, responds well to local or systemic therapy, and has a favourable prognosis...
  35. ncbi request reprint Exciting new developments in chronic lymphocytic leukemia: an introduction and an editorial
    Kanti R Rai
    Semin Hematol 41:189-90. 2004
  36. ncbi request reprint ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
    Laura Z Rassenti
    Chronic Lymphocytic Leukemia Research Consortium, University of California, San Diego, La Jolla 92093, USA
    N Engl J Med 351:893-901. 2004
    ....
  37. pmc In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
    Bradley T Messmer
    Institute for Medical Research, North Shore LIJ Research Institute, Manhasset, New York 11030, USA
    J Clin Invest 115:755-64. 2005
    ..A correlation between birth rates and disease activity and progression appears to exist, which may help identify patients at risk for worsening disease in advance of clinical deterioration...
  38. pmc Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18)
    Brian A McCarthy
    Laboratory of Experimental Immunology, The Feinstein Institute for Medical Research, Manhasset, New York 11030, USA
    Mol Med 14:618-27. 2008
    ..It is not clear if this surface membrane expression is a passive consequence of the apoptotic process or an active attempt by the B cell to abort cell death by stabilizing the plasma membrane...